Approved for Treatment of moderate-to-severe asthma in patients aged 6 years and older with an allergic component not adequately controlled by inhaled corticosteroids, Treatment of chronic idiopathic urticaria in adults and adolescents. Omalizumab is a recombinant humanized monoclonal antibody that selectively binds to immunoglobulin E (IgE), preventing IgE from binding to high-affinity…
Loading full data from Know Your Drugs Institute…